Veracyte Stock Price, News & Analysis

Veracyte, Inc. (Nasdaq: VCYT) will release its financial results for Q1 2022 on May 3, 2022, after market close. The management will host a conference call at 4:30 p.m. ET to discuss results and provide a business update. U.S. participants can dial (855) 541-0980, while international participants can call (970) 315-0440, using Conference ID 3848138. The call will be webcast live on the company's website, with a replay available later. Veracyte specializes in diagnostic tests that enhance patient care and reduce unnecessary procedures.

Veracyte (Nasdaq: VCYT) announced its participation in Cowen’s 42^nd Annual Health Care Conference on March 8, at 12:50 p.m. Eastern Time. CEO Marc Stapley and CFO Rebecca Chambers will present, with a live audio webcast available on Veracyte’s website. A replay will be accessible for 90 days post-event.

Veracyte is a global diagnostics company focused on improving patient care through advanced diagnostic tests that address prevalent cancers, reducing unnecessary procedures and time to treatment.

Veracyte reported significant growth in Q4 2021, achieving $67.3 million in revenue, a 95% increase year-over-year. For the full year, total revenue reached $219.5 million, up 87%. However, operating expenses rose 104% to $227.0 million, primarily due to acquisition-related costs, leading to a net loss of $75.6 million, a 116% increase. The company anticipates 2022 revenue to be between $260 million and $275 million, marking a growth of 18% to 25%.

Veracyte, Inc. has appointed Annie McGuire as senior vice president and general counsel, effective immediately. McGuire, with extensive experience from Fortune 100 and healthcare companies, will manage the company's legal functions and report directly to CEO Marc Stapley. Previously, she was general counsel at Rakuten Medical and has held leadership positions at MyoKardia, where she played a key role in its $13 billion acquisition by Bristol Myers Squibb. Her appointment is anticipated to enhance Veracyte's strategic vision in diagnostics.

Veracyte, Inc. has appointed Jonathan Wygant as its new chief accounting officer, effective immediately. Wygant will manage all global accounting operations, financial reporting, and tax functions, reporting directly to Rebecca Chambers, the CFO. He previously held finance leadership roles at several healthcare companies, including as corporate controller at Biosplice Therapeutics. This leadership change aims to strengthen Veracyte's accounting operations as the company pursues its global strategic vision.

Veracyte, Inc. (Nasdaq: VCYT) will release its financial results for Q4 and full-year 2021 after market close on February 28, 2022. A conference call is scheduled at 4:30 p.m. ET to discuss these results and provide a general business update. Investors can access the conference call via the company's website, where a replay will also be available afterward. Veracyte is a diagnostics company focused on improving patient care through genomic tests for various cancers and diseases, leveraging advanced technology to expedite diagnosis and treatment.

Veracyte, Inc. (Nasdaq: VCYT) presented new data at the 2022 ASCO GU Symposium confirming the efficacy of the Decipher Prostate Genomic Classifier for prostate cancer treatment selection. This Phase 3 study validates the Classifier's role as a prognostic biomarker for men with intermediate-risk prostate cancer, providing critical insights for personalized treatment. Key findings indicate that patients classified as Decipher ‘high-risk’ have significantly worse clinical outcomes compared to ‘low-risk’ patients. This innovative approach could greatly enhance treatment strategies for prostate cancer patients.

Veracyte (Nasdaq: VCYT) announced that CEO Marc Stapley and CFO Rebecca Chambers will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16 at 2:20 p.m. Eastern Time. A live audio webcast of the presentation will be available on Veracyte’s website, with a replay accessible for 90 days afterward. Veracyte specializes in diagnostics, offering tests for various cancers and other diseases, utilizing genomic advancements to enhance patient care.

Veracyte (NASDAQ: VCYT) announced the presentation of six abstracts at the 2022 ASCO GU Cancers Symposium, occurring from February 17-19, 2022. The studies focus on the Decipher genomic classifier as a prognostic biomarker for intermediate-risk prostate cancer, marking a significant late-stage validation of gene expression classifiers. The presentations will share insights on risk stratification and treatment guidance for urologic cancers.

The event takes place in San Francisco, Calif..